Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 01/21/2028 | CALL | $80.00 | 9,378 | +3,121 | +49.88% |
| 09/18/2026 | CALL | $50.00 | 4,014 | +1,070 | +36.35% |
| 01/02/2026 | CALL | $55.00 | 1,786 | +1,009 | +129.86% |
| 12/19/2025 | CALL | $52.00 | 2,435 | +960 | +65.08% |
| 12/19/2025 | CALL | $75.00 | 11,858 | +758 | +6.83% |
| 12/19/2025 | CALL | $55.00 | 29,037 | +746 | +2.64% |
| 12/19/2025 | PUT | $45.00 | 27,353 | -384 | -1.38% |
| 01/16/2026 | CALL | $60.00 | 22,208 | -439 | -1.94% |
| 12/19/2025 | PUT | $50.00 | 20,088 | -488 | -2.37% |
| 01/16/2026 | CALL | $50.00 | 20,252 | -766 | -3.64% |
| 06/18/2026 | CALL | $45.00 | 3,769 | -780 | -17.15% |
| 12/19/2025 | CALL | $50.00 | 43,908 | -6,378 | -12.68% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Harbor Capital Appreciation Fund | 0.18% | 3.11M | 481.53M |
| Washington Mutual Investors Fund | 0.09% | 1.51M | 234.45M |
| Vanguard U.S. Growth Fund | 0.07% | 1.27M | 196.47M |
| Loomis Sayles Growth Fund | 0.07% | 1.18M | 183.13M |
| Fidelity Blue Chip Growth Fund | 0.07% | 1.13M | 175.35M |
| Amana Mutual Funds Trust-Growth Fund | 0.06% | 1M | 155.09M |
| PGIM Jennison Growth Fd | 0.05% | 828.11k | 128.15M |
| Blackrock Equity Dividend Fund | 0.04% | 712k | 110.18M |
| New Perspective Fund Inc | 0.04% | 691.44k | 107M |
| Price (T.Rowe) International Stock Fund | 0.04% | 674k | 104.3M |
2 Predictions for Novo Nordisk in 2026
12/14 10:30 am
The Motley Fool
Read moreFDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch
12/12 09:54 am
Benzinga
Read more3 Absurdly Cheap Stocks That Look Like Steals Right Now
12/10 01:22 pm
The Motley Fool
Read moreWhy Wave Life Sciences Stock Crushed it Again Today
12/09 08:19 pm
The Motley Fool
Read morePrediction: This Surprising Growth Stock Will Reach -- and Stay in -- the Trillion-Dollar Club in 2026.
12/09 02:15 pm
The Motley Fool
Read moreWhy Wave Life Sciences Stock Vaulted 146% Higher on Monday
12/08 07:30 pm
The Motley Fool
Read moreEli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip?
12/06 06:07 pm
The Motley Fool
Read moreDo These 3 Healthcare Stocks Need a Checkup?
12/05 05:05 pm
The Motley Fool
Read moreThis Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?
12/05 12:05 pm
The Motley Fool
Read moreWhat Trends Are Defining the Hemophilia Inhibitors Market Growth?
12/04 10:00 am
GlobeNewswire Inc.
Read more1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year
12/03 02:10 pm
The Motley Fool
Read moreSickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight
12/03 02:00 pm
GlobeNewswire Inc.
Read moreInsulin Analog Market Forecasting USD 25.29 Billion Valuation by 2034
12/03 12:00 pm
GlobeNewswire Inc.
Read moreScholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away
12/03 10:34 am
The Motley Fool
Read moreMedicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock?
12/03 10:30 am
The Motley Fool
Read moreZepbound Just Got Cheaper: Lilly Cuts Prices On LillyDirect To Broaden Access
12/01 04:41 pm
Benzinga
Read moreThis 7% Yielder Could Be a Top AI Play
11/30 05:04 pm
The Motley Fool
Read moreHuman Growth Hormone Injection Market Size Expected to Reach USD 8.54 Bn by 2035
11/27 11:00 am
GlobeNewswire Inc.
Read morePrediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029
11/27 09:15 am
The Motley Fool
Read moreAnti-Obesity Drugs Market Size to Reach $35.52 Billion by 2032, Driven by Advancements in Weight Management Therapies and Rising Obesity Prevalence | SNS Insider
11/27 08:54 am
GlobeNewswire Inc.
Read morePrediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031
11/27 08:18 am
The Motley Fool
Read moreNovo Nordisk Wants FDA Nod For A Higher-Dose Wegovy
11/26 02:27 pm
Benzinga
Read moreDid Pfizer Just Say "Checkmate" to Novo Nordisk?
11/26 05:15 am
The Motley Fool
Read moreNovo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says
11/25 02:24 pm
Benzinga
Read moreChronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight
11/25 02:00 pm
GlobeNewswire Inc.
Read moreJ&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline
11/25 01:22 pm
Benzinga
Read moreNovo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients
11/25 11:08 am
Benzinga
Read moreAdalyon Appoints Ulrik Zeuthen as CEO to Drive Next Phase of Growth in AI-driven Speech-based Biomarkers and Behavioural Analytics for Optimising Clinical Trials
11/25 05:00 am
GlobeNewswire Inc.
Read moreWhy Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?
11/24 12:17 pm
Benzinga
Read moreNovo Nordisk's Blockbuster Weight-Loss Drug Flops In Alzheimer's Trial
11/24 09:06 am
Benzinga
Read moreNovo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
11/23 05:30 am
The Motley Fool
Read more2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?
11/22 07:13 pm
The Motley Fool
Read more3 Top Dividend Stocks to Buy in November
11/22 02:05 pm
The Motley Fool
Read moreNovo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer's
11/21 11:36 am
Benzinga
Read moreNovo Nordisk Leans Into Affordability Amid Rising Competition
11/17 02:01 pm
Benzinga
Read moreNovo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control
11/17 11:11 am
Benzinga
Read moreLifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
11/17 09:00 am
GlobeNewswire Inc.
Read moreThis Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000?
11/17 06:25 am
The Motley Fool
Read moreEli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks?
11/16 01:10 pm
The Motley Fool
Read moreMangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
11/13 08:37 pm
GlobeNewswire Inc.
Read moreNovo Nordisk A/S: Candidate for the Board of Directors will not seek election
11/13 06:38 pm
GlobeNewswire Inc.
Read more1 Incredible Reason to Buy LLY's Stock in November
11/13 05:25 am
The Motley Fool
Read moreNovo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
11/12 10:24 am
Benzinga
Read moreNovo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India
11/11 04:16 pm
Benzinga
Read moreWho's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
11/11 05:25 am
The Motley Fool
Read moreNovo Nordisk Gains as Strategic Exit From Metsera Deal Restores Investor Trust
11/10 01:41 pm
Investing.com
Read moreHuge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump
11/09 06:31 am
The Motley Fool
Read moreHims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
11/09 05:35 am
The Motley Fool
Read moreThinkCareBelieve: Week 42 of America's Climb into the Golden Age
11/08 11:05 pm
GlobeNewswire Inc.
Read more